BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28533226)

  • 1. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2
    Reinholz MM; Chen B; Dueck AC; Tenner K; Ballman K; Riehle D; Jenkins RB; Geiger XJ; McCullough AE; Perez EA
    Clin Cancer Res; 2017 Aug; 23(15):4203-4211. PubMed ID: 28533226
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
    Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
    J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
    Dueck AC; Reinholz MM; Geiger XJ; Tenner K; Ballman K; Jenkins RB; Riehle D; Chen B; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow J; Harris LN; Ingle JN; Lingle WL; Perez EA
    Clin Cancer Res; 2013 Oct; 19(20):5798-807. PubMed ID: 23965903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
    Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
    Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
    Perez EA; Baehner FL; Butler SM; Thompson EA; Dueck AC; Jamshidian F; Cherbavaz D; Yoshizawa C; Shak S; Kaufman PA; Davidson NE; Gralow J; Asmann YW; Ballman KV
    Breast Cancer Res; 2015 Oct; 17(1):133. PubMed ID: 26429296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
    Filipits M; Dafni U; Gnant M; Polydoropoulou V; Hills M; Kiermaier A; de Azambuja E; Larsimont D; Rojo F; Viale G; Toi M; Harbeck N; Prichard KI; Gelber RD; Dinh P; Zardavas D; Leyland-Jones B; Piccart-Gebhart MJ; Dowsett M;
    Clin Cancer Res; 2018 Jul; 24(13):3079-3086. PubMed ID: 29530933
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
    Caparica R; Ma Y; De Angelis C; Richard F; Desmedt C; Awada A; Piccart M; Perez EA; Moreno-Aspitia A; Badve S; Thompson EA; de Azambuja E
    Clin Breast Cancer; 2022 Jun; 22(4):308-318. PubMed ID: 34980541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
    Perez EA; Reinholz MM; Hillman DW; Tenner KS; Schroeder MJ; Davidson NE; Martino S; Sledge GW; Harris LN; Gralow JR; Dueck AC; Ketterling RP; Ingle JN; Lingle WL; Kaufman PA; Visscher DW; Jenkins RB
    J Clin Oncol; 2010 Oct; 28(28):4307-15. PubMed ID: 20697084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
    Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
    J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
    J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
    Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM
    J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
    Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
    Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
    Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
    Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
    Pivot X; Fumoleau P; Pierga JY; Delaloge S; Bonnefoi H; Bachelot T; Jouannaud C; Bourgeois H; Rios M; Soulié P; Jacquin JP; Lavau-Denes S; Kerbrat P; Cox D; Faure-Mercier C; Pauporte I; Gligorov J; Curtit E; Henriques J; Paget-Bailly S; Romieu G
    Eur J Cancer; 2017 Aug; 81():151-160. PubMed ID: 28624696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.